Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa | Zendy

Chandy C. John | Zendy; Robert O. Opoka | Zendy; Teresa S. Latham | Zendy; Heather Hume | Zendy; Catherine Nabaggala | Zendy; Phillip Kasirye | Zendy; Christopher M. Ndugwa | Zendy; Adam Lane | Zendy; Russell E. Ware | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa

Author(s) -

Chandy C. John,

Robert O. Opoka,

Teresa S. Latham,

Heather Hume,

Catherine Nabaggala,

Phillip Kasirye,

Christopher M. Ndugwa,

Adam Lane,

Russell E. Ware

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2000146

Subject(s) - sickle cell anemia , anemia , medicine , disease

Hydroxyurea has proven safety, feasibility, and efficacy in children with sickle cell anemia in sub-Saharan Africa, with studies showing a reduced incidence of vaso-occlusive events and reduced mortality. Dosing standards remain undetermined, however, and whether escalation to the maximum tolerated dose confers clinical benefits that outweigh treatment-related toxic effects is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research